Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 8OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 291Carcinoma, Renal Cell 172Kidney Neoplasms 118Urinary Bladder Neoplasms 102Breast Neoplasms 70Neoplasms 64Melanoma 48Testicular Neoplasms 45Sarcoma 45Wilms Tumor 44Lung Neoplasms 42Ovarian Neoplasms 41Neuroblastoma 39Colonic Neoplasms 34Lymphoma, Non-Hodgkin 32Lymphoma 31Osteosarcoma 28Neoplasm Metastasis 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Uterine Cervical Neoplasms 24Colorectal Neoplasms 23Carcinoma, Transitional Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Medulloblastoma 22Urethral Neoplasms 21Central Nervous System Neoplasms 21Carcinoma, Ovarian Epithelial 21Burkitt Lymphoma 21

Interventions

ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms, Glandular and Epithelial × Genitourinary × Clear all
NCT07574541 2026-06-04

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡